



[Go to Product page](#)

Datasheet for ABIN7488078

Recombinant anti-CCR2 (Plozalizumab Biosimilar) antibody

Overview

| | |
|----------------|--------------------------------|
| Quantity: | 100 µg |
| Target: | CCR2 (Plozalizumab Biosimilar) |
| Reactivity: | Human |
| Host: | Mammalian Cells |
| Antibody Type: | Recombinant Antibody |
| Clonality: | Monoclonal |
| Application: | ELISA |

Product Details

| | |
|------------------|--|
| Purpose: | Plozalizumab Biosimilar - Anti-CCR2, CD192 mAb |
| Isotype: | IgG1 kappa |
| Characteristics: | Antibody Type: IgG1-kappa |
| Grade: | Research Grade |

Target Details

| | |
|--------------|---|
| Target: | CCR2 (Plozalizumab Biosimilar) |
| Target Type: | Biosimilar |
| Background: | MLN-1202,anti-CCR2,hu1D9 Plozalizumab is a humanized monoclonal antibody that targets CCR2 chemokine receptors found on the surface of white blood cells such as macrophages and monocytes. Plozalizumab has been investigated to treat Atherosclerosis. CCR2 is supposed to play an important role in |

Target Details

the trafficking of monocytes and macrophages to sites of inflammation.

CAS-No: 1610761-46-0

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS pH 7.5

Storage: -80 °C

Storage Comment: store at -80°C